Gilead draws harsh reviews as PhIII for $21B Immunomedics drug underwhelms Wall Street

Back in the summer of 2020, Gilead acquired Immunomedics for $21 billion hoping to turn its breast cancer drug Trodelvy into a megablockbuster. On Monday morning, however, Gilead got some news that it won’t be a slam dunk. The big biotech revealed Trodelvy met its primary endpoint of progression-free survival…

...

Click to view original post